Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

ABSTRACT

The present invention relates to methods for treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (NAFLD) and its sequelae, a lipodystrophic syndrome or a combination thereof with the selective PPARy agonist, INT131 and optionally vitamin E or compositions thereof. NAFLDs that may be treated with methods and compositions of the present invention include, but are not limited to, simple nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Lipodystrophic syndromes that may be treated with the methods and compositions of the present invention include, but are not limited to, generalized lipodystrophy including congenital generalized lipodystrophy and acquired generalized lipodystrophy and/or partial lipodystrophy, including congenital partial lipodystrophy and acquired partial lipodystrophy, all of which may or may not include hyperlipidemia and/or hyperglycemia and may or may not include NAFLD.

BACKGROUND OF THE INVENTION

A healthy liver contains a minimal amount of fat. When a significant number (usually more than 5%) of the cells in the liver have abnormal fat accumulation the liver is considered diseased. Fatty liver diseases consist of two main categories based on whether they are caused by excessive alcohol consumption or not. Fatty liver diseases that are not caused by excessive alcohol consumption are termed nonalcoholic fatty liver diseases (“NAFLDs”), which consist of simple nonalcoholic fatty liver (“NAFL”) and in a significant portion of subjects proceeds to a more severe form associated with inflammation, called nonalcoholic steatohepatitis (“NASH”). NAFL and/or NASH may also include scarring of the liver known as liver fibrosis or in a more severe form, liver cirrhosis. Scarring of the liver reduces liver function up to and including liver failure.

NAFLDs have many non-mutually exclusive causes including malnutrition, overeating, obesity, diabetes, medications and hyperlipidemia. However, the main cause of NAFLDs appears to be high-fat, high-calorie diets leading to an excess amount of energy which exceeds the storage capacity of adipose tissue and thus is stored in the liver. NASH is positively correlated with the metabolic syndrome (i.e. diseases related to diabetes mellitus type 2, such as insulin resistance, trunk obesity, hyperlipidemia and hypertension) although the correlation is not 100%.

Over the past 20 years, the number of cases of NAFLDs has nearly doubled. Almost 30% of people in developed countries are estimated to have NAFL or NASH including 20% of adults in the United States. The best method of prevention and treatment of NAFLDs include a low-calorie diet and exercise. However, due to voluntary non-compliance, an inability to exercise and/or long term diet restriction, many patients must also be treated with pharmaceuticals.

Current pharmaceutical treatments that have been proposed or tested in prior trials, although not yet approved for NAFLDs include vitamin C, vitamin E, betaine, metformin, orlistat, selenium, thiazolidinediones (“TZDs”), urodeoxycholic acid, and pentoxifilline. Ongoing FDA-approved trials include: GR-MD-02, a galactose-containing polysaccharide manufactured by Galectin Therapeutics Inc., for the treatment of NASH with attendant liver fibrosis; a Hadassah, LTD drug technology, which includes feeding patients with natural antibodies to intestinal flora associated with NAFLDs; and obeticholic acid for treatment of NASH with attendant liver fibrosis being conducted by Intercept Pharmaceuticals, Inc.

A diverse array of other agents have been proposed as either direct or indirect treatments for NAFLDs (e.g.: interleukin-22 (U.S. Patent Application Publication No. 20140377222); piperine derivatives (U.S. Patent Application Publication No. 20140371271); nuclear transport modifiers (U.S. Patent Application Publication No. 20140336113) and Bifidobacterium pseudocatenulatum strain CECT 7765 (U.S. Patent Application Publication No. 20140369965).

Lipodystrophic syndromes present with either a complete or partial lack of adipose tissue. Although less prevalent than NAFLDs, lipodystrophic syndromes have a more severe presentation. Patients with generalized lipodystrophy (i.e. congenital and/or acquired) have metabolic abnormalities consistent with the metabolic syndrome and hepatomegaly due to fatty infiltration of the liver. Patients with congenital partial lipodystrophy also present with metabolic complications including insulin resistance, usually accompanied by hypertriglyceridemia, hyperlipidemia and possibly hyperglycemia.

The treatment plan for lipodystrophic syndrome is similar to that for NAFLDs including diet, exercise and treatment of underlying metabolic disturbances. Many of the same drugs used to treat NAFLDs have been implemented to treat lipodystrophic syndromes. A recently approved medication for treating congenital complete generalized lipodystrophy associated with metabolic dysfunction is leptin.

Despite the attention that NAFLDs and lipodystrophic syndromes have recently received there is still no effective pharmaceutical options for their treatment. The lack of an effective treatment combined with the rapid rise in prevalence of the diseases creates an immediate need in the art for new drugs and methods of treatment for NAFLDs and/or lipodystrophic syndromes.

BRIEF SUMMARY OF THE INVENTION

The present invention provides a method of treating a disease associated with insulin resistance selected from a nonalcoholic fatty liver disease (“NAFLD”), a lipodystrophic syndrome or a combination thereof comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt, ester or prodrug thereof.

The compound of formula (I) is also known as 2,4-Dichloro-N-[3,5-dichloro-4-(3-quinolinyloxy)phenyl]benzenesulfonamide (ACD/IUPAC name) and is referred to as INT131 throughout the specification.

In another embodiment, the present invention provides a method of treating a disease associated with insulin resistance selected from an NAFLD, a lipodystrophic syndrome or a combination thereof comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) and an effective amount of vitamin E.

In a preferred embodiment, the present invention provides a method of treating a disease associated with insulin resistance selected from an NAFLD, a lipodystrophic syndrome or a combination thereof comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) and an effective amount of vitamin E concomitantly, simultaneously or consecutively.

In another preferred embodiment, the present invention provides a method of treating a disease associated with insulin resistance selected from an NAFLD, a lipodystrophic syndrome or a combination thereof comprising administering to a subject in need thereof a compound of formula (I) at amount of from about 0.1 to about 10.0 milligrams (“mg”) per day, preferably from about 1 to about 2 mg per day, more preferably about 1 or about 2 mg per day and vitamin E at an amount from about 1 to about 10,000 international units (“IU”) per day, preferably from about 400 to about 1,000 IU per day, and more preferably at about 400, 800 or 1,000 IU per day.

The present invention provides a method of treating an NAFLD comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt, ester or prodrug thereof.

In a preferred embodiment the present invention provides a method of treating nonalcoholic fatty liver (NAFL) comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating NAFL with attendant liver fibrosis comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating NAFL with attendant liver cirrhosis comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating nonalcoholic steatohepatitis (NASH) comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating NASH with attendant liver fibrosis comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating NASH with attendant liver cirrhosis comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating an NAFLD comprising administering to a subject in need thereof from about 0.1 to about 10.0 mg per day of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof, preferably from about 1 to about 5 mg per day, more preferably about 1 or about 2 mg per day.

In another preferred embodiment the present invention provides a method of treating an NAFLD comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the method provides an NAFLD activity score (“NAS”) of 7 or less, preferably 5 or less and more preferably 3 or less.

In another embodiment the present invention provides a pharmaceutical composition for the treatment of a disease associated with insulin resistance selected from an NAFLD, a lipodystrophic syndrome or a combination thereof comprising INT131.

In another preferred embodiment the present invention provides a pharmaceutical composition for the treatment of an NAFLD comprising INT131.

In another preferred embodiment the present invention provides a pharmaceutical composition for the treatment of a lipodystrophic syndrome comprising INT131.

In another embodiment the present invention provides a method of treating a lipodystrophic syndrome comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In a preferred embodiment the present invention provides a method of treating a generalized lipodystrophy comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating a congenital generalized lipodystrophy comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating an acquired generalized lipodystrophy comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating a partial lipodystrophy comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating a congenital partial lipodystrophy comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating an acquired partial lipodystrophy comprising administering to a subject in need thereof a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another embodiment the present invention provides a method of treating hyperlipidemia comprising administering to a subject suffering from a lipodystrophic syndrome and hyperlipidemia a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another embodiment the present invention provides a method of treating hyperlipidemia comprising administering to a subject suffering from a lipodystrophic syndrome, an NAFLD and hyperlipidemia a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating hyperglycemia comprising administering to a subject suffering from lipodystrophic syndrome and hyperglycemia a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

In another preferred embodiment the present invention provides a method of treating hyperglycemia comprising administering to a subject suffering from a lipodystrophic syndrome, an NAFLD and hyperglycemia a therapeutically effective amount of INT131 or a pharmaceutically acceptable salt, ester or prodrug thereof.

DETAILED DESCRIPTION OF THE INVENTION

INT131 is compound distinct from thiazolidinediones that activates a specific subset of PPARy-dependent pathways. Specifically, INT131 was designed to activate anti-inflammatory, anti-oxidative stress, and neuroprotective pathways without activating edemagenic and lipogenic inducing pathways, which are activated by thiazolidinedione (TZD) drugs.

The free base and certain pharmaceutically acceptable salts of INT131 are described in International Patent Publication No. WO/2001/000579, and U.S. Pat. Nos. 6,583,157 B2 and 7,041,691 B1. U.S. Pat. No. 7,223,761 B2 discloses that the benzenesulfonic acid (besylate) salt of INT131, and polymorphs thereof.

Definitions

As used herein the term “nonalcoholic fatty liver disease” or “NAFLD” refers to all diseases of the liver caused by steatosis that are not a result of the excessive consumption of alcohol. NAFLDs include, but are not limited to, simple nonalcoholic fatty liver (“NAFL”), nonalcoholic steatohepatitis (“NASH”), NAFL with attendant liver fibrosis, NAFL with attendant liver cirrhosis, NASH with attendant liver fibrosis, NASH with attendant liver cirrhosis, and fatty liver disease resulting from hepatitis, obesity, diabetes, insulin resistance, hypertriglyceridemia, abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolman disease, pregnancy or lipodystrophy.

As used herein the term “simple nonalcoholic fatty liver disease” or “NAFL” refers to a liver that has greater than 5% by weight fat content.

As used herein the term “lipodystrophic syndrome” or “lipodystrophic syndromes” or “lipodystrophy” refers to a disorder characterized by either complete or partial lack of adipose tissue in a subject affected by the disorder. Partial lack of adipose tissue can be localized to a particular anatomical region of the body of the subject and may include a gain of adipose tissue in a separate anatomical region. Lipodystrophy may also present with hyperlipidemia and/or hyperglycemia.

As used herein the term “hyperlipidemia” refers to lipid or triglyceride content of the blood exceeding normal values well known in the art.

As used herein the term “hyperglycemia” refers to glucose content of the blood exceeding normal values well known in the art.

As used herein the term “generalized lipodystrophy” refers to a disorder characterized by a complete lack of adipose tissue. Generalized lipodystrophy may be either congenital or acquired.

As used herein the term “congenital generalized lipodystrophy” or “CGL” refers to a disorder characterized by a complete lack of adipose tissue as a result of a congenital defect. Congenital generalized lipodystrophy, although not limited to the following types, may occur as a result of Seip-Berardinelli syndrome, a mutation to the AGPAT2 gene (i.e. Type 1 CGL), a mutation to the BSCL2 gene (i.e. Type 2 CGL), a mutation to the CAV1 gene (i.e. Type 3 CGL) or a mutation to the PTRF gene (i.e. Type 4 CGL).

As used herein the term “acquired generalized lipodystrophy” refers to a disorder characterized by a complete lack of adipose tissue as a result of the subject's post-birth environment.

As used herein the term “congenital partial lipodystrophy” refers to a disorder characterized by a partial lack of adipose tissue as a result of a congenital defect. Congenital partial lipodystrophy, although not limited to the following types, may occur as a result of Kobberling's syndrome (i.e. familial partial lipodystrophy (“FPLD”) type 1), Dunnigan's syndrome (i.e. FPLD type 2), a mutation to the PPARy gene (i.e. FPLD type 3), a mutation to the AKT2 gene (FPLD type 4), a mutation to the PLIN1 gene (i.e. FPLD type 5), a mutation to the CAV1 gene, or mandibuloacral dysplasia.

As used herein the term “acquired partial lipodystrophy” refers to a disorder characterized by a partial lack of adipose tissue as a result of the subject's post-birth environment.

As used herein the term “subject” refers to animals such as mammals, including but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In preferred embodiments, the subject is a human.

As used herein the term “therapeutically effective amount” refers to that amount of the compound being administered sufficient to prevent development of or alleviate to some extent one or more of the symptoms or the signs of the condition or disorder being treated.

The terms “treat”, “treating” and “treatment” refer to a method of alleviating or abrogating a disease and/or its attendant symptoms or signs.

The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either net or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either net or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isbutyric, oxalic, maleic, malonic, benzoic, succinic, suberic, fumeric mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S. M., et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present inventions contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

The neutral forms of the compounds may be registered by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

In additional to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug. They may, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmacological compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example, without limitation, of a prodrug would be a compound of the present invention which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound of the invention.

Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.

The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (³H), iodine-125 (¹²⁵I) or carbon-14 (¹⁴C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

As used herein the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from a combination of the specified ingredients in the specified amounts.

Embodiments of the Invention

New uses of the known compound INT131 have now been discovered. Specifically, INT131 has now been discovered to treat disorders associated with insulin resistance selected from an NAFLD, a lipodystrophic syndrome or a combination thereof. As seen below, treatment with INT131 of trial subjects suffering from an NAFLD results in a reduction in the subject's NAS.

In particular, the compound of formula (I),

has been found to be unexpectedly effective for NAFLDs.

This compound is also known as INT131.

Compositions of the Invention

The present invention also provides pharmaceutical compositions that comprise compounds of the present invention formulated together with one or more pharmaceutically acceptable carriers. The pharmaceutical compositions can be specially formulated for oral administration in solid or liquid form, for parenteral administration or for rectal administration.

The pharmaceutical compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally, intracisternally, intravaginally, transdermally (e.g. using a patch), transmucosally, sublingually, pulmonary, intraperitoneally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray. The terms “parental” or “parenterally,” as used herein, refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

In another aspect, the present invention provides a pharmaceutical composition comprising a component of the present invention and a physiologically tolerable diluent. The present invention includes one or more compounds as described above formulated into compositions together with one or more physiologically tolerable or acceptable diluents, carriers, adjuvants or vehicles that are collectively referred to herein as diluents, for parenteral injection, for intranasal delivery, for oral administration in solid or liquid form, for rectal or topical administration, among others.

Compositions suitable for parenteral injection may comprise physiologically acceptable, sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), vegetable oils (such as olive oil), injectable organic esters such as ethyl oleate, and suitable mixtures thereof.

These compositions can also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.

Suspensions, in addition to the active compounds, may contain suspending agents, as for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these substances, and the like.

Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound may be mixed with at least one inert, pharmaceutically acceptable excipient or carrier, such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; e) solution retarding agents such as paraffin; f) absorption accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol, glycerol monostearate, and PEG caprylic/capric glycerides; h) absorbents such as kaolin and bentonite clay and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills and granules can be prepared with coatings and shells such as enteric coatings and other coatings well-known in the pharmaceutical formulating art. They may optionally contain opacifying agents and may also be of a composition such that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.

Besides inert diluents, the oral compositions may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals which are dispersed in an aqueous medium. Any, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are natural and synthetic phospholipids and phosphatidyl cholines (lecithins) used separately or together.

Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.

Example

Protocol

A 48 week double blind, placebo controlled, randomized, parallel group study will be conducted to evaluate the effect of INT131 on hepatic histology of obese patients with NASH. Specifically, at least 225 subjects are chosen that fit the following criteria: (1) age 18 to 75 years old; (2) body mass index (BMI) greater than 25 kg/m² and less than 40 kg/m²; (3) NAFLD fibrosis score greater than or equal to 1.0 and less than 4.0; (4) average daily alcohol consumption of 10 g/day or less; (5) NAFLD activity score (“NAS”) of 3 or greater; (6) histologically proven steatohepatitis on a diagnostic liver biopsy performed within 6 months of randomization, confirmed central laboratory reading of slides (steatosis >5% lobular inflammation, any amount of ballooning); (7) women who meet the following criteria: women of childbearing potential with a negative urine pregnancy test at Screening who agree to use 1 or more approved methods of birth control during the study. Approved methods of birth control are: hormonal contraception, intrauterine device, diaphragm plus spermicide, female condom plus spermicide. Abstinence from heterosexual intercourse will be acceptable only if it is the preferred and usual lifestyle of the subject regardless of study participation; abstinence should be practiced for the duration of the study and until 8 weeks after taking the last dose of study drug; or women who have been postmenopausal for at least 2 years (with amenorrhea for at least 1 year) or have had a hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation prior to signing the informed consent form; (8) no participation in a previous study of NASH; (9) no participation in a study with an investigational drug or device study within the 28 days prior to randomization (Week 0/Day 0) or a period equal to 5 times the half-life of the investigational agent (whichever is longer); (10) no use of the following medication within the last 6 months or during the trial (anti-depressant, antipsychotics or other dopamine antagonists, dietary supplements including tryptophan or vitamin E, estrogens, progestins, glucocorticosteroids, insulin, thiazolidinediones, dipeptidy peptidase (DPP) IV inhibitors and other GLP-1-based therapies, orlistat, phentermine, topiramate, lorcaserin, buproprion or other weight reducing medication, metreleptin, vitamin E, multivitamins, ferrum, ursodeoxycholic acid, interferon, tamoxifene, methotrexate, amiodarone, biologic agents, any medication affecting hemostasis, such as antiplatelet agents, aspirin or oral anticoagulants); (10) No alanine amino transferase (ALT) and aspartate amino transferase (AST) of 5×the upper limit of normal (“ULN”); (11) no unexplained serum creatinine phosphokinase (CPK) >3×ULN; (12) no known alcohol and/or any other drug abuse or dependence within the last 5 years; (13) no average daily alcohol consumption of >20 g/day (0.7 ounces); (14) no regular consumption >3 caffeinated beverages per day (ie, coffee, sodas, not chocolate and caffeinated tea; (15) no type 1 diabetes mellitus (16) no uncontrolled glycemia (Glycosolated Hemoglobin A1C≥9%) and/or HbA1C increment >1% within 6 months prior to enrollment or OR type 2 diabetes with recurrent major hypoglycemic or hypoglycemic unawareness, (17) no known history or the presence of clinically significant cardiovascular disease, New York Heart Association (NYHA) Class III or IV congestive heart failure; (18) no known history or the presence of clinically significant gastrointestinal, metabolic disorder other than diabetes mellitus, neurologic, pulmonary, endocrine, psychiatric, neoplastic disorder, or nephrotic syndrome; (19) No history of bariatric surgery; (20) no presence or history of malignancy, except for successfully treated non metastatic basal or squamous cell carcinoma of the skin and carcinoma in situ of the cervix; (20) no major systemic infections, including human immunodeficiency virus (HIV): (21) no unresolved Hepatitis B or C infection (defined as positive hepatitis B surface antibody [HBsAb], hepatitis B core antibody [HBcAb], or hepatitis C virus [HCV] RNA); (22) no history of any disease or condition known to interfere with absorption, distribution, metabolism or excretion of drugs including bile salt metabolism, (ie, inflammatory bowel disease), previous intestinal surgery; chronic pancreatitis, celiac disease or previous vagotomy; (23) no weight loss >5% in the 6 months prior to randomization; (24) no uncontrolled hypertension (systolic blood pressure >160 mmHg and diastolic blood pressure >100 mmHg) (Mancia 2013)<3 months prior to Screening; (25) no breastfeeding and pregnant mothers, and/or women who plan to get pregnant during the course of the study; (26) no medical history or multiple drug allergies (anaphylactoid drug reaction in >2 drug groups); (27) no uncontrolled hyperthyroidism or hypothyroidism; (28) no use of the following medications ≤12 months prior to screening: antidepressant, antipsychotics or other dopamine antagonists, dietary supplements including tryptophan, estrogens, progestins, glucocorticosteroids, insulin, thiazolidinediones, dipepetidy peptidase (DPP) IV inhibitors and other glucagon-like (GLP-1) based therapies and/or Pioglitazone, sibutramine, orlistat, rimonabant, phentermine, topirarmate, vitamin E, multivitamins, ferrum, ursodeoxycholic acid, interferon, tamoxifen, methotrexate, amiodarone, biologic agents, an medication affecting homostasis, such as antiplatelet agents aspirin or oral anti-coagulants; (Homeopathic and/or alternative treatments; (29) no use of vitamin E, fish oil, or urosodeoxycholic acid <3 months prior to diagnostic liver biopsy; (30) no renal dysfunction estimated glomerular filtration rate (eGFR)<40; (31) no presence of any other condition or illness that in the opinion of the Investigator would put the subject at increased risk or affect the ability to participate in the study; (32) not unable or unwilling to sign informed consent; and (33) no instance of liver cirrhosis (in the alternative, a trial may be developed wherein the subjects may have instances of liver cirrhosis) or clinical evidence of decompensated chronic liver disease: radiological or clinical evidence of ascites, current or previous hepatic encephalopathy and evidence of portal hypertension or varices on endoscopy; other liver disease (viral hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis and overlap syndromes, drug-induced liver disease, hemochromatosis, Wilson's disease, al-antitrypsin deficiency); type 1 diabetes mellitus; type 2 diabetes with recurrent uncontrolled hyperglycemia or major hypoglycaemia or hypoglycaemic unawareness; valvular heart disease; depression or thoughts of suicide; severe anemia or leucopenia; pancreatitis; uncontrolled hypothyroidism or hyperthyroidism or other endocrinopathy such as adrenal insufficiency; renal failure; thrombotic disorders; any malignancy; breastfeeding, pregnancy or plan for pregnancy; addiction to any drug; medical history of multiple drug allergies (defined as anaphylactoid drug reactions) or allergy to INT 131. In another example of this trial subjects would be allowed to be on stable doses of antidiabetic medications such as metformin for the duration of the study.

The at least 225 subjects are randomly and evenly assigned to 3 groups of equal number of subjects. The first group receives 1.25 mg of INT131 once per day for 48 weeks, the second group receives 2 mg of INT131 once per day for 48 weeks, and the third group receives a placebo once per day for 48 weeks. In another example, the study could be terminated at the 24 week time point. In yet another example, the study would last up to 72 weeks. At the beginning of the trial (i.e. week 0) and at least weeks 4, 12, 24, 48 and 50 and up to 10 total visits, each of the at least 225 subjects are tested for changes in NAS, steatosis grade (via fatty liver index, “FLI”), portal and lobular inflammation grade, ballooning grade and fibrosis stage (via NAFLD fibrosis score), as described by Kleiner et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology 2005, 41(6), 1313-21. Each of the 300 subjects are also tested for changes in 1) anthropometric characteristics (ie. weight, BMI, waist and hip circumference); 2) liver function tests (i.e. aspartate aminotransferase (AST), alkaline aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), creatinine phosphokinase (CPK), and total and direct bilirubin); 3) serum lipid profile (i.e. total cholesterol, triglycerides, and high-density lipoprotein cholesterol); 4) insulin resistance (via oral glucose tolerance test “OGTT” and/or homeostatic model of assessment-insulin resistance, “HOMA-IR”); 5) adipokines (i.e. leptin, adiponectin and vaspin), markers of liver function (such as fetuin and irisin); 6) results of nuclear magnetic resonance spectroscopy (“NMR-spec”) of liver; 7) bone density and body fat mass and distribution via dual-energy x-ray absorptiometry (DEXA) at all or some of the above time points as indicated; 8) high sensitivity C reactive protein (“hCRP”); liver fibrosis markers ELF′ (such as hyaluronic acid (“HA”), procollagen III amino terminal peptidase (“PIIINP”), and metalloproteinase 1 tissue inhibitor (“TIMP-1”); and bone markers (such as procollagen type 1 amino-terminal propeptide (“P1NP”) and osteocalcin). Patient will undergo liver biopsies at screening and at Week 9 and Week 48. Pharmacokinetic (“PK”) samples will be collected at baseline and at Week 9, Week 28 and Week 48. Pharmacodynamic (“PD”) samples will be collected at baseline and at Week 9 and Week 48.

The following tasks will be completed on Day 1 (1) perform an abbreviated physical examination including vital signs, weight, height, waist and hip circumference; (2) medical history review; (3) obtain fasting morning blood and urine samples for safety labs including serum lipid profile and liver function tests; (4) obtain blood samples for PK analyses; (5) obtain blood samples for PD analyses; (5) perform liver biopsy if not performed in last two weeks; (5) for woman of child bearing potential perform urine pregnancy test; (6) concomitant medication review; (7) document any serious adverse events since signing of informed consent; (8) dispense study medication.

The following tasks will be completed during Week 5: (1) perform an abbreviated physical examination including vital signs, weight, height, waist and hip circumference; (2) obtain fasting morning blood and urine samples for safety labs including serum lipid profile and liver function tests; (3) concomitant medication review; (4) record all adverse events and (5) record returned study medication and dispense study medication.

The following tasks will be completed during Week 9: (1) perform an abbreviated physical examination including vital signs, weight, height, waist and hip circumference; (2) obtain fasting morning blood and urine samples for safety labs including serum lipid profile and liver function tests; (3) obtain blood samples for PK analyses; (4) obtain blood samples for PD analyses; (5) concomitant medication review; (6) record all adverse events; and (7) record returned study medication and dispense study medication.

The following tasks will be completed during Weeks 17, 23, 28, 35, and 41: (1) perform an abbreviated physical examination including vital signs, weight, height, waist and hip circumference; (2) obtain fasting morning blood and urine samples for safety labs including serum lipid profile and liver function tests; (3) obtain blood samples for PK analyses; (4) obtain blood samples for PD analyses at week 28 only; (5) record all adverse events; (6) record returned study medication and dispense study medication.

The following tasks will be completed during Week 48 or Early Termination Visit: (1) perform an abbreviated physical examination including vital signs, weight, height, waist and hip circumference; (2) obtain fasting morning blood and urine samples for safety labs including serum lipid profile and liver function tests; (3) obtain blood samples for PK analyses; (4) obtain blood samples for PD analyses; (5) obtain ultrasound guided liver biopsy after collection of blood samples. To be done after collection of all blood samples; (6) calculate NFS; (7) concomitant medication review; (8) record all adverse events and (9) record returned study medication. Sufficient data will also be collected during all time points to calculate the indexes outlined below.

Endpoints

The primary endpoint of the study will be a 2 point reduction NAS steatosis (part of NAS) grade at week 48 compared to baseline. The secondary endpoints of the study will include: (1) change in NAS steatosis grade at week 9 compared to baseline; (2) change in hepatic histology as assessed by NAS at week 9 and week 48 compared to baseline: (3) changes in NAFLD fibrosis score (NFS) at week 9 and 48 compared to baseline; (4) changes in Fatty liver index (FLI) at week 9 and 48 compared to baseline; (5) changes in BMI and waist to hip ratio at Week 9 and 48 compared to baseline; and (6) changes from baseline in the following parameters will be evaluated at weeks 9 and 48: (i) liver function tests including γ-glutamyl transferase (GGT); (ii) high sensitivity CRP; (iii) serum lipid profile; (iv) insulin resistance; (v) adiponectin; (vi) liver fibrosis biomarker via ELF: HA, PIIINP, andTIMP-1; and (vii) bone markers: P1NP and Osteocalcin.

Safety

All patients will be provided with a diet and mild aerobic exercise routine. Blood and urine samples for safety labs will be collected at screening and at Week 9 and Week 48 or more frequently if warranted. Safety endpoints will include: (1) monitoring treatment emergent adverse events; (2) valuation of subject discontinuation and withdrawal information; (3) assessment of changes in safety laboratory parameters, including hematology, clinical chemistry, pregnancy tests and (4) assessment of changes in vital signs, physical examination and electrocardiogram findings.

Methods

BMI is calculated by the formula: body weight (kg)/height² (m²).

HOMA-IR is calculated by the formula: glucose (mmol/L)×insulin (μU/mL)/22.5.

NAFLD fibrosis score is calculated by the formula: −1.675+0.037*age (years)+0.094*BMI (kg/m²)+1.13*IFG (impaired fasting glucose)/diabetes mellitus (yes=1, no=0)+0.99*AST/ALT ratio−0.013*platelet (*10⁹ /L)−0.66*albumin (g/dL).

FLI is calculated by the formula: (e^(0.953*Loge(triglycerides)+0.139*BMI+0.718*Loge(GGT)+0.053*(waist circumference)−15.745)) (1+e^(0.953*Loge(triglycerides)+0.139*BMI+0.718*Loge(GGT)+0.053*(waist circumference)−15.745))*100.

Insulin sensitivity will be quantified by the quantitative insulin sensitivity check index (QUICKI) using the formula: QUICKI=1/[log(glucose) (mg/dL)+log(insulin) (μU/mL)]

NAS is calculated by the unweighted sum of the scores for steatosis, lobular inflammation and ballooning, which are determined via liver biopsy. Steatosis is scored from 0 to 3 wherein 0 indicates less than 5% of hepatocytes contain abnormal fat accumulation, 1 indicates 5-33%, 2 indicates 34-66% and 3 indicates more than 66%. Lobular inflammation is scored from 0 to 3 wherein 0 indicates no inflammation, 1 indicates less than two, 2 indicates from 2 to 4 and 3 indicates more than 4. Ballooning is scored from 0 to 2 wherein 0 indicates no hepatocyte ballooning, 1 indicates few ballooned hepatocytes and 2 indicates many ballooned hepatocytes. Thus, the total for NAS ranges from 0 to 8. For more detail see Kleiner et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology 2005, 41(6), 1313-21 and LaBrecque D, et al., (ed.) World Gastroenterology Organisation Global Guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, 2012, June, 1-29 available at http://www.worldgastroenterology.org/NAFLD-NASH.html, each of which is incorporated herein by reference in its entirety.

NMR-spec is conducted under the following conditions: 1H-MRS is used to calculate the precise fat content of the liver. Single-voxel MR spectra will be acquired in a 3T MM Scanner with the integrated body coil using a point-resolved spectroscopy (PRESS) technique and local shimming. Voxels (size 20×20×20 mm³) will be placed in the right liver lobe (segment VII) trying to avoid bile ducts and larger vessels. Scans will be acquired during a matter of seconds while participants are holding their breath to avoid artifacts. TR=3,500 ms, TE=25 ms, 512 data points, bandwidth, BW=1,000 Hz/pixel, without water suppression.

Results

Subjects receiving either 1.25 or 2 mg of INT131 have a reduction in their NAS, steatosis grade, portal and lobular inflammation grade, ballooning grade and/or fibrosis stage when comparing week 0 to week 48, which is statistically significant versus the placebo group. Subjects receiving either 1.25 or 2 mg of INT131 also have an improvement in their liver function test(s) as well as most if not all other metabolic parameters outlined above. 

1-33. (canceled)
 34. A method of treating nonalcoholic steatohepatitis (NASH) comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein the subject is a human, and wherein the therapeutically effective amount is from about 0.1 mg to about 10 mg.
 35. The method of claim 34, wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is from about 0.5 mg to about 5 mg.
 36. The method of claim 35, wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is from about 1 mg to about 3 mg.
 37. The method of claim 36, wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is about 1 mg.
 38. The method of claim 36, wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is about 1.5 mg.
 39. The method of claim 36, wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is about 2 mg.
 40. The method of claim 36, wherein the therapeutically effective amount of the formula (I), or a pharmaceutically acceptable salt thereof, is about 3 mg.
 41. The method of claim 34, wherein the compound of the formula (I) is administered as a pharmaceutically acceptable salt.
 42. The method of claim 41, wherein the pharmaceutically acceptable salt of the compound of formula (I) is the besylate salt.
 43. The method of claim 42, wherein the amount of the besylate salt of the compound of formula (I), is equivalent to from about 0.5 mg to about 5 mg of the free base.
 44. The method of claim 43, wherein the amount of the besylate salt of the compound of formula (I), is equivalent to from about 1 mg to about 3 mg of the free base.
 45. The method of claim 44, wherein the amount of the besylate salt of the compound of formula (I), is equivalent to about 1 mg of the free base.
 46. The method of claim 44, wherein the amount of the besylate salt of the compound of formula (I), is equivalent to about 1.5 mg of the free base.
 47. The method of claim 44, wherein the amount of the besylate salt of the compound of formula (I), is equivalent to about 2 mg of the free base.
 48. The method of claim 44, wherein the amount of the besylate salt of the compound of formula (I), is equivalent to about 3 mg of the free base. 